Clinical studies investigating the effect of LAMP-1 mRNA-loaded DC vaccines in glioblastoma have observed exceptional tumor-specific CD4+ and CD8+ T cell response and extended overall patient survival (Phase I, NCT00626483, NCT00639639; Phase II, NCT02366728) [251,252]. Here, CD8A is linked to neoplasm.